CEO Brochure Excellence 2010

Wednesday 1st December 2010 at Radisson Blu Hotel, Galway City
KINDLY SUPPORTED BY
Irish Medical Technology
CEO Forum 2010
Irish Medical Technology CEO Forum 2010
Programme
13.00 to 14.00
Registration & Lunch
14.00 to 15.40
KEYNOTE SESSION: ‘GLOBAL INSIGHTS’
Chair: Brian O’Neill, Manager, Life Sciences, Enterprise Ireland
•
•
Recognise and appreciate the effect that global trends are having on business in Ireland
Understand and influence our national response to dealing with change and recovery
Speakers & Panel
Pat Gallagher, Outgoing Chair IMDA/ Irish Industry ins ights
10 min
Pat Delaney, Director of Sectors, Enterprise and Regional Policy
10 min
Roland Pfleger, VP & GM, Respiratory & Monitoring Solutions, EMEA, Covidien
35 min
Bryan Mohally, Member/ Innovation Taskforce Implementation Group
25 min
(VP Supply Chain Johnson & Johnson)
Panel debate / Q&A
15.40 to 16.10
Coffee Break
16.10 to 17.35
‘EMBRACING CHANGE’
20 min
Chair: Gus Jones, Manager, Medical Technologies Division, IDA Ireland
•
•
Hear from peers as to how they have transformed their organisations
Meet and network with our industry leaders
Speakers & Panel
17.35 to 17.40
John Elwood, Vice President, Global Manufacturing, KCI Medical
15 min
Matt McBride, Plant Manager, Harmac Medical
15 min
Frank Keane, MD Vitalograph
15 min
John Power, CEO Aerogen
15 min
Panel Discussion / Q&A
25 min
Closing Remarks
5 min
Irish Medical Technology CEO Forum 2010
Chairs Session One and Two
Brian O’Neill
Life Sciences, Enterprise Ireland
Brian O’Neill is Manager for Lifesciences at Enterprise Ireland, the agency
responsible for the internationalisation of indigenous Irish industry.Brian
has worked for over 15 years, both nationally and internationally, in the
lifesciences sector, in a variety of private sector and government roles,
including basic and applied research, entrepreneur, technology transfer
and business development.
In his current role, Brian (and his team of dedicated functional specialists – business development advisors,
technologists, international marketing and human resource development experts) is responsible for the development
and implementation of the strategic plan required to drive the continued global expansion of the 250+ Irish Lifesciences
businesses. In addition, he also plays a key role in shaping the Irish ‘ecosystem’ to ensure its long-term development
and integration.
Brian had a Ph.D. in Human Molecular Genetics from Trinity College Dublin and a 1st Class Honours MBA from
University College Dublin.
More information on Enterprise Ireland:
Enterprise Ireland is the government organisation responsible for the development and growth of Irish enterprises in
world markets. With 31 offices across the World, Enterprise Ireland works in partnership with Irish enterprises to help
them start, grow, innovate and win export sales on global markets, supporting sustainable economic growth, regional
development and secure employment.
Gus Jones
G
Manager, Medical Technologies Division
M
G Jones manages IDA Ireland’s Medical Technologies Division. His last
Gus
as
assignment was to open IDA’s office in China.
H has wide experience of working with global companies in Information Technology, Life
He
Sciences, International Financial Services and Digital Media companies. Previously he was
Sc
based in the Boston and New York offices of IDA Ireland.
ba
Gus has a BSc degree in Computer Science from University College Cork and an MBA from
G
University College, Dublin.
U
Irish Medical Technology CEO Forum 2010
Speakers
Pat Gallagher
IMDA Chairman
Pat Gallagher is General Manager of Baxter
Healthcare’s Irish Manufacturing Operations,
a position he took up in 2002. Having held
various management positions with Abbott
both in Ireland and overseas, Pat returned to
Ireland to join Boston Scientific in Galway in
1997 before moving to Baxter to head up its
Irish operations and later expanding his role to
include U.K. manufacturing.
Ba
Baxter
employs over 1,000 people
in Mayo and a further 200 between
its European Financial Shared Services
Centre in Dublin and its Sales &
Ce
Marketing functions in Dublin and
Ma
Belfast.
Be
Pat Delaney
Director of Sectors, Enterprise
and Regional Policy, IBEC
Pat Delaney is the director responsible for
business sectors, enterprise and regional
policy in IBEC.
This division provides detailed technical, regulatory and
policy representation to over 50 specific industry groups
within the Confederation.
Prior to being appointed to the Executive Board of the
Confederation, Pat was Director of the Small Firms
Association from 1998 to 2006.
He is a member of a number of public bodies including
the Social Partnership Plenary Council, the National
Competitiveness Council, the Better Regulation Forum,
the High Level Group on Manufacturing, the Irish
Payments Organisation, and, is a former member of
the Pensions Board.
Abstract:
We have every good reason to feel proud of the role
that the Irish medical technology industry plays in
advancing patient health and improving the quality
and efficiency of health care systems right across the
world. Ireland’s medtech sector has evolved into one
of the leading clusters for medical device and diagnostic
products globally.
Looking to the future of the medical technology sector
globally, we can see that the pace of change in the
sector is increasing at an unrelententing speed. Patient
demographics, healthcare reform, hospital consolidation,
austerity measures, technological change, regulation are
but some of the influencers that we are aware of and
incorporating into our plans. While challenging for us
all, these changing dynamics provide us with enormous
opportunities. To make innovation work for us, have to
work to develop an ecosystem in which each element,
and each interaction, supports the economy and society
and we are succeeding.
Abstract:
The very real strengths and successes
of Irish-based businesses have recently
tended to get overshadowed given the
intense media focus on the fiscal and
banking crises.
Ireland is in many ways well positioned
to take advantage of emerging global trends
ends in the
sector; activities located in Ireland are becoming
increasingly sophisticated and driven by R&D, and the
taxation regime in Ireland is supportive. In terms of
bringing order to our public finances — necessary for
maintaining our economic independence — IBEC has
two overarching priorities: credible progress on reducing
the fiscal deficit and substantive measures to address
the jobs crisis.
Irish business has the scale and scope needed to
generate substantial and sustainable growth and the
medtech sector will form an integral part of this.
Roland Pfleger
Vice President and General Manager,
Respiratory and Monitoring Solutions, EMEA
Roland Pfleger, is an Austrian national and
holds a ‘best honours’ degree in Economics,
from Vienna University (1986), majoring in
Advertising, Market Research and Controlling.
He is fully bilingual in German and English,
and also has a fair knowledge of Portuguese.
Pfleger has worked for leading
healthcare companies including
he
Eli Lilly, Boston Scientific and currently
Covidien. He worked for Eli Lilly
Co
between 1988 and 1997. During
be
this time, he worked as a financial
thi
analyst; a Business Development
an
Manager, Pharmaceutical Division,
Ma
Eastern Europe; and as the General Manager of Lilly
Portugall and
became the Controller for Lilly Germany.
P
db
In August 1997, Pfleger joined Boston Scientific, where
he became the CEO of Schneider Europe following its
acquisition by Boston Scientific from Pfeizer. He was
Director for Strategic Planning before joining Boston
Scientific as the General Manager of Germany.
Pfleger joined Covidien (or Tyco Healthcare as it was)
in August 2003 and was General Manager of Tyco
Healthcare Germany. He is now the Vice President
and General Manager, Respiratory and Monitoring
Solutions, EMEA. In 2010, Pfleger joined the Board
of Eucomed, the leading Medical Technology Trade
Association in Europe.
Bryan Mohally
Vice President Supply Chain Operations,
Johnson & Johnson
Bryan Mohally is currently VP Supply Chain
Operations with Johnson & Johnson Inc
USA, and is also a board member of several
other J&J affiliates in Ireland. Previously for
many years he was Managing Director of
Janssen Pharmaceutical Ltd, a subsidiary
of Johnson & Johnson.
He is a Past President of
PharmaChemical
Ireland, the
Ph
representative body within IBEC for
rep
the pharmaceutical and chemical
sector, and he also serves on the
se
Board of Directors of the Cork Cancer
Bo
Research Centre, a cancer research
Re
partnership between U.C.C. and
pa
the Cork Hospitals. He has recently served on the
Government Innovation Taskforce and currently serves
as a member of the Implementation Team.
Abstract:
■ Covidien is a global healthcare company based in
Ireland that develops and markets advanced surgical
instruments, procedure-enabling devices, patient
care and safety products, pharmaceutical products,
imaging solutions for the diagnosis and treatment of
diseases, and nuclear medicines.
■ Our mission is to innovate and develop new products
that improve patient outcomes and enable surgeons
and other healthcare professionals to deliver the best
possible patient care.
■ Covidien employs 42,000 people worldwide with
over 7,000 employees in Europe. Our products are
available in over 140 countries. Covidien recently
reorganised the global business units to the
following: Medical Devices, Pharmaceutical Products,
and Medical Supplies.
Covidien in Ireland
■ Covidien has a well-established presence in Ireland
and has operated in the country for nearly 30 years.
We employ almost 2,000 people in Ireland. This is
our largest employee base in Europe.
■ Covidien has four manufacturing sites, a sales and
customer service operations, and our principal
executive office in the country.
■ Tullamore: Medical Supplies
■ Galway:
Respiratory and Monitoring Solutions
■ Athlone:
Respiratory and Monitoring Solutions
■ Dublin:
Imaging Solutions (Damastown)
Customer Service Center (Cherrywood)
Principal Executive Office (Dublin 2)
Abstract:
In 2008, the Government set out the overarching
framework for rebuilding and repositioning Ireland as a
Smart Economy, and creating “The Innovation Island”.
The Innovation Taskforce was subsequently established
to focus on measures to progress one pillar of Building
Ireland’s Smart Economy : “Building the innovation
or ‘ideas’ component of the economy through the
utilisation of human capital – the knowledge, skills and
creativity of people – and the ability and effectiveness
of that human capital to translate ideas into valuable
processes, products and services.”
The Innovation Taskforce completed its work in March
2010 and published its report, Innovation Ireland –
Report of the Innovation Taskforce, which provides
an important road map for positioning Ireland as an
international innovation development hub. A high-level
Innovation Taskforce Implementation Committee (ITFIC)
was established, chaired by the Minister for Enterprise,
Trade and Employment, to oversee implementation of
the recommendations outlined in the report.
John Elwood
Vice President, Global Manufacturing, KCI
Jo Elwood is a University of
John
Lim
Limerick graduate with first class
ho
honours degree. In Manufacturing
En
Engineering and a Ph.D. in
aautomation.
u
He was the winner
o
off the 2002 MEETA National
M
Maintenance Award and runner
up in 2004 Chartered Engineer of
th
the Year Award.
Previous Industrial experience includes:
■ Bose, Carrickmacross
■ Several leadership positions with Hewlett
Packard’s ink-jet division in Leixlip, Co. Kildare
■ General Manager, Celestica, Galway, and
John joined KCI in September ’07 as General Manager
for KCI’s Ireland start-up. He is currently Vice President
of Global Manufacturing for KCI’s Active Healing
Solutions business, with responsibility for global
manufacturing, global manufacturing engineering
and global procurement.
Abstract:
KCI opened its manufacturing facility in Athlone in late
2007. Today this facility manufactures a wide range of
FDA Class II products. Depending on the product, the
volumes range from a few hundred units annually to
several million units annually. This presentation focuses
on KCI Manufacturing Irelands strategy to automate the
manufacturing of its high volume products, and become
more cost competitive than KCI’s existing low cost
supply strategy.
■ KCI.
Matt McBride
Plant Manager, Harmac Medical Products
Matt Mc Bride is Plant Manager with Harmac
Medical Products Ltd. in Castlerea, Ireland.
Matt graduated from Athlone Instititute of
Technology in 1982 with a degree in Polymer
Science, trained with Tyco Healthcare as a Six
Sigma Black Belt and received an MBA from
Coventry University in 2006.
Matt has worked in the Medical Device Industry for
over 25 years and has extensive experience in the
implementation of Lean Manufacturing, Six Sigma and
Automation to eliminate waste and variation to deliver
bottom line results.
Matt’s presentation will briefly outline how Harmac’s
implementation of Operational Excellence has helped
Harmac create competitive advantage for their
customers while also delivering significant business
improvements at their manufacturing sites.
Abstract:
Harmac Medical Products Ltd, is a full-service, vertically
integrated, contract medical device company. From
concept to design, manufacturing and packaging,
Harmac produce high-quality, custom, single-use
devices for a global customer base that includes many
Fortune 500 companies.
Harmac Medical Products were successful in winning
the IMDA Gold Award for Operational Excellence in
2009 and this presentation will
outline some of the key enablers
that have helped Harmac to create
competitive advantage for our
customers, while also delivering
significant internal business
improvements, at all our sites.
Frank Keane
General Manager, Vitalograph Ireland
Frank has been General Manager of
Vitalograph, Ireland since 2004. He was
educated at Trinity College and graduated
with a B.Eng in Electronic Engineering
from UL (1982) and an M.Sc in
Management Science.
He was previously General Manager of Parthus
Technologies GPS Division in Northampton UK and VP
of Product marketing for Parthus.
Prior to that Frank was Director of Product Marketing
and Engineering Manager at Artesyn Technolgies and
previous to that he was R&D Manager and Design
Engineer at various Midwest Multinationals and
indigenous companies.
Abstract:
Vitalograph was formed as Garthur in 1963 to develop
and market the worlds first ‘Office’ spirometer. The
product was an instant success and the name of the
product; the ‘Vitalograph’ quickly became adopted
as the company name. Vitalograph opened in Ireland
in 1974 and soon afterwards Ireland became the
company’s sole R&D and manufacturing facility,
which it has remained to this day.
John Power
CEO, Aerogen
Founder of five hi-tech start-up’s, over a thirty
year career, John is a passionate innovator in
both technology and business.
His company Aerogen, based in
Galway, is regarded as a world leader
Ga
in acute care drug delivery having
created a range of award winning high
cre
performance aerosol therapy products
pe
for patients in the ICU setting. Aerogen
is ttoday working with its partners to
deliver innovative solutions for a broad
de
respiratory and systemic conditions and
spectrum of respira
is pioneering the use of its technology to create new
markets in both surgical and ophthalmic drug delivery.
John holds qualifications in mechanical and production
engineering and computer technology along with an
MBA from Oxford Brookes University.
Vitalograph’s core business is the
design, manufacture and marketing
of spirometers and associated
products. A spirometer is a device
used to measure lung function, which
is achieved by the subject blowing into
o the device.
Vitalograph is the leader in this niche field and has been
for some years. However three other markets have
complemented the traditional core market in recent
years. The first market is that of consumables such
as filters, valves and noseclips. The second market is
Clinical Drug Trials where Vitalograph has participated
for close to ten years and have become number two in
the world in respiratory drug trials. The product here is
a combination of hardware, software and services such
as data management and project management. The last
market is services such as product servicing, technical
support and ‘whole’ product definition items such as
training and trainers.
The presentation will focus on a change program,
initiated at the end of 2005, to substantially change
the organisation. It will examine the change processes
used, as well as the results of the change, what worked
and what didn’t.
Abstract:
Aerogen is a specialty medical device and drug
delivery company specialising in the design,
manufacture, marketing of nebulization systems,
aimed at the critical care respiratory market. Aerogen’s
patented OnQ™ aerosol technology is an integral part of
its drug delivery systems.
Founded in Galway in 1997, Aerogen has grown to
become the global leader in acute care aerosol drug
delivery equipment and today its Aeroneb products
play a critical role in treating patients on life-support
ventilation, as well as home care offerings in over 50
counties worldwide. Aerogen currently employs a
growing team of 40 primarily Science and Engineering
graduates, many to PhD level.
Aerogen is dynamic and evolving company, focusing
on innovative products that create new market
opportunities. It is this innovative approach that has
seen Aerogen register over 40 international patents and
continually develop new products, leading the way in
the aerosolized drug delivery market.
Medical Technology Industry
Excellence Awards 2010
jointly hosted by
Enterprise Ireland, IDA Ireland and
Irish Medical Devices Association.
For more information contact Sinead Keogh;
IMDA, Confederation House
84/86 Lwr Baggot St, Dublin 2
Tel: 01 6051538 Email: [email protected]